BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) is a blank-check company organized to pursue a business combination in the healthcare and oncology sector. The company filed a Form 10-Q with the SEC on May 15, 2025, covering its most recent quarterly reporting period, indicating the vehicle remained in its pre-merger operating phase at that time. BBOT is focused on the biopharmaceutical and life-sciences industry, reflecting continued investor appetite for SPAC structures targeting oncology and therapeutic development companies. The filing, bearing accession number 0001213900-25-044424, is part of the company's standard reporting obligations as a publicly traded special purpose acquisition company. Sign up at SpacDesk for full data on BBOT, including deal timeline, extension history, warrant activity, and comparable oncology-focused transactions.